Pharmaceuticals

Hengrui Pharma

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Huaren Pharmaceutical Receives Approval for Clinical Trials of HRS-3005

Hengrui Pharmaceutical Repurchased 12,056,200 A-shares in April

Citi Gives Hengrui Medicine H Shares 'Buy' Rating with Target Price

UBS Adjusts Hengrui Medicine's Profit Forecast and Maintains Buy Rating

Hengrui Medicine reports 21.78% increase in first quarter net profit

Hengrui Pharma released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 8.141 B (forecast CNY 8.277 B), actual EPS CNY 0.34 (forecast CNY 0.3305)

Hengrui Medicine's Subsidiary's SHR-A1811 Inclusion in Breakthrough Therapy List

Hengrui Medicine Subsidiary Obtains Clinical Trial Approval for HRS9531 Injection

Hengrui Medicine's Subsidiary's Drug SHR-A2102 Included in Breakthrough Therapy List

Hengrui Medicine's subsidiary receives clinical trial approval for new heart failure drug HRS-7156

Hengrui Pharma to Release FY2026 Q1 Earnings on April 22 After-Market (BJT), Forecast Revenue CNY 8.807 B, EPS CNY 0.3305

600276

588130

M Stanley reports that HENGRUI PHARMA has formed a USD15.2 billion strategic partnership with Bristol-Myers Squibb, covering 13 pre-clinical assets. The deal includes a USD600 million upfront payment, annual payments of USD350 million for 2027-2028, and up to USD14.3 billion in milestone payments. This collaboration is expected to enhance HENGRUI's R&D and globalization capabilities, particularly in the immunology market in China. M Stanley maintains an Overweight rating on HENGRUI PHARMA with a target price of HKD92 for its H shares.

AASTOCKS News

Bristol Myers Squibb

ChinaAMC SSE STAR Biology and Medicine ETF

Morgan Stanley

HENGRUI PHARMA

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Bristol-Myers Squibb Company

M Stanley: HENGRUI PHARMA  Forms USD15.2B Strategic Partnership with Bristol-Myers Squibb Company  to Accelerate Globalization

01276

PILL

159859

512290

159849

159102

520880

516500

Jiangsu Hengrui Pharmaceutical has signed a $15.2 billion collaboration and licensing agreement with Bristol Myers Squibb (BMS). Hengrui's shares rose 5.3% in Hong Kong and 4.84% in Shenzhen following the announcement. The deal includes 13 preclinical programs, with BMS paying up to $950 million upfront. This partnership highlights China's growing role in innovative drug development, although experts note the need for further advancements in the pharmaceutical value chain. Hengrui will receive tiered royalties on sales outside mainland China, Hong Kong, and Macau.

SCMP

Direxion Pharma & Medical Bull 3X

iShares US Pharma

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI Biotechnology Theme ETF

TIGERMED

Tigermed

上海镁信健康科技集团股份有限公司

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

SBIO

Bristol Myers Squibb (BMS) and Hengrui Pharma have formed a global strategic collaboration and licensing agreement covering 13 early-stage programs in oncology, hematology, and immunology. Announced on May 12, 2026, the deal includes a $950 million payment structure, with BMS paying $600 million upfront. The collaboration aims to leverage BMS's global capabilities and Hengrui's discovery platforms to accelerate the development of new therapies. BMS will hold exclusive rights to Hengrui-originated assets outside certain territories, while Hengrui will manage proof-of-concept activities and may co-develop selected assets.

Pharmexec

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

ProShares Ultra Health Care ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

VG Health

Invesco Nasdaq Biotechnology ETF

<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

E Fund CSI Biotechnology Theme ETF

Direxion S&P Biotech Bear 3X

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

520690

159506

513120

Hengrui Pharmaceutical's shares surged after announcing a USD15.2 billion deal with Bristol Myers Squibb (BMS) to co-develop 13 innovative drugs. Hengrui's stock rose 4.8% in Shanghai and 5.7% in Hong Kong. The agreement grants Hengrui exclusive rights in China, while BMS retains global rights. BMS will pay Hengrui USD950 million upfront, with additional milestone payments, and Hengrui will receive royalties on net sales outside China. The deal awaits regulatory approval and is expected to finalize in Q3 2023, enhancing both companies' drug development capabilities.

Yicai

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS

Hengrui Pharma(600276.SH)

M Stanley: HENGRUI PHARMA Forms USD15.2B Strategic Partnership with Bristol-Myers Squibb Company to Accelerate Globalization

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

China’s Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS